This dispatch covers GLP-1s Are Shrinking More Than Your Waistline in the Metabolic research category, authored by Editorial Team, The Peptide Dispatch, originally published in The Peptide Dispatch on March 16, 2026. Estimated reading time: 8 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
GLP-1 receptor agonists (semaglutide, tirzepatide) have evolved over the past three years from glucose-and-weight interventions into broad metabolic-and-inflammatory modulators with effects across four emerging domains: addiction and reward signalling, systemic inflammation, cardiac remodelling (notably HFpEF in STEP-HFpEF and SUMMIT), and renal function (FLOW trial in CKD/T2D). Mechanistically, GLP-1 receptors are expressed on mesolimbic reward neurones, on macrophages and other immune cells, on cardiomyocytes, and on renal tubular cells — providing direct molecular substrate for the diverse effects observed. The class reduces hsCRP by 25-40% in published trials. The principal methodological challenge in the literature is disentangling GLP-1-receptor-specific effects from secondary effects of weight loss and improved glycaemia. Safety signals remain consistent with the established class profile — GI adverse events are dose-limiting; pancreatitis and medullary thyroid concerns remain monitored.
Glucagon-like peptide-1 (GLP-1) receptor agonists — most prominently semaglutide (Ozempic, Wegovy) and the dual-incretin tirzepatide (Mounjaro, Zepbound) — were originally developed and approved on the strength of their effects on glycaemic control in type 2 diabetes and, subsequently, on body weight in obesity. Over the past three years, however, an expanding clinical and preclinical literature has begun to map a far broader portfolio of biological effects that extend well beyond appetite suppression and gastric emptying delay. This dispatch synthesises the most consequential of those emerging findings across four domains — addiction and reward signalling, systemic inflammation, cardiovascular and cardiac remodelling, and renal function — and discusses what they collectively suggest about GLP-1 receptor biology and the future trajectory of the drug class. The first and most-discussed novel finding concerns addictive behaviours. Multiple cohort studies, observational analyses of insurance-claims databases, and a growing number of small randomised investigations have reported that patients on GLP-1 receptor agonists experience reduced craving and reduced consumption across several substances of abuse — alcohol, nicotine, stimulants, and, in animal models, opioids. The mechanistic hypothesis centres on GLP-1 receptor expression in the mesolimbic reward circuitry: GLP-1 receptors are present on dopaminergic neurones in the ventral tegmental area, on neurones in the nucleus accumbens, and on glutamatergic projections from the prefrontal cortex into both regions. Activation of these receptors appears to dampen drug-induced dopamine release and reduce the conditioned reinforcing properties of multiple addictive substances. Several Phase 2 trials of semaglutide in alcohol use disorder are underway; preliminary results presented at major conferences in 2024 and 2025 have shown promising effect sizes, although peer-reviewed publication of full datasets is still pending in so…
All information is presented for Research Use Only (RUO). Not medical advice.